Colour enhancement

From PsychonautWiki
Jump to: navigation, search

Color enhancement can be described as the experience of colors becoming extremely bright or vivid and standing out.[1][2] During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.[3][4][5][6][7][8][9][10][11]

Studies have also suggested an accompanying effect of decreased hue discrimination resulting in anecdotal accounts of perceiving colours which are seemingly impossible.[3][4]

Colour enhancement is often accompanied by other coinciding effects such as acuity enhancement and pattern recognition enhancement.[9][10] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA or 3-MeO-PCP.

Image examples

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

Experience reports

Annectdotal reports which describe this effect with our experience index include:

See also

External links


  1. Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887.
  2. Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64.
  3. 3.0 3.1 Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451.
  4. 4.0 4.1 Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567.
  5. Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346.
  6. Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42.
  7. Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753.
  8. Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26.
  9. 9.0 9.1 Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4.
  10. 10.0 10.1 Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014.
  11. Juszczak, G. R., & Swiergiel, A. H. (2013). Recreational use of D-lysergamide from the seeds of Argyreia nervosa, Ipomoea tricolor, Ipomoea violacea, and Ipomoea purpurea in Poland. Journal of psychoactive drugs, 45(1), 79-93.